Enzalutamide, one of the few treatments shown to extend the
lives of men with advanced prostate cancer, has been
provisionally approved for use on the NHS in England and Wales,
NICE have announced today (Friday 18 October 2013) - a decision
which could mean extra months of life to countless men.
Owen Sharp, Chief Executive of Prostate Cancer UK, said: ‘This
is great news for men. We fought long and hard to have abiraterone,
which works in a similar way, available on the NHS. It isn't
successful for every man, and we need clinicians to have options at
their disposal to do what counts - extend the lives of men with
this disease when other options have run out. We need to see NICE
confirm this decision as soon as possible and for the SMC to follow
"The truth is that there are precious few treatments for a
condition which not only seriously impinges upon the life of those
with advanced disease, but kills one man each hour. This is a
victory for these men today. However, we need to keep on leading
change, and working with others to see more treatments emerge for
the future. Men continue to deserve better."
 This draft decision will now be consulted on until 9
November before NICE make a final announcement on whether the
drug is to be licensed.